Skip to content
value.today
CNS Response, Inc. logo

CNS Response, Inc.

Total raised
$7 M
4 rounds on record
Latest round
$3 M
Jan 2011
First round on record
Jun 2009
Today
Went public
See the company page

CNS Response, Inc. is listed today as Emmaus Life Sciences, Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of CNS Response, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2020$4 MPrivate placement after listing$2 to $10 million

CNS Response, Inc.: Private sale, Sep 2020

Investors in this round

18 investors had bought by the notice of Oct 9, 2020: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, other: Five year common stock warrants to purchase a total of up to 1,840,000 shares of Emmaus common stock at an exercise price of $2.00 per share and placement agent warrants to purchase up to 75,000 share
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
more than a year
Issuer's revenue
$25 million to $100 million
Sales commissions
none
Finders' fees
$157,500
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joseph Sherwood · Executive Officer
  • Willis Lee · Executive Officer, Director
  • Yutaka Niihara · Executive Officer, Director
  • Ian Pine Zwicker · Director
  • Jane Pine Wood · Director
  • Masaharu Osato · Director
  • Robert Dickey · Director
  • Wei Peu Zen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • T.R. Winston & Company LLC (CRD 1415264) · Los Angeles, CaliforniaSold in CA

Remarks in the notice

  • On fees: “Paid in the form of the placement agent warrants referred to in item 9 based upon the total exercise price of the placement agent warrants.”

Signed by Dale Short, General Counsel. Source: SEC Form D and 1 amendment, newest notice filed Oct 9, 2020. Read the notice at the SEC.

optionsSEC
Jan 2011$3 MNo. 4$2 to $10 million

CNS Response, Inc.: Raise no. 4, Jan 2011

Investors in this round

12 investors had bought by the notice of May 9, 2011: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$50,000
What was sold
options or other rights to buy securities, other: DEBT CONVERTIBLE INTO EQUITY
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$105,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel T. Hoffman · Executive Officer
  • George Carpenter · Director, Executive Officer
  • Michael T. Darkoch · Executive Officer
  • Paul T. Buck · Executive Officer
  • David B. Jones · Director
  • George T. Kallins · Director
  • Henry T. Harbin · Director
  • Jerome B. Vaccaro · Director
  • John Pappajohn · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Antaeus Capital, Inc. · Los Angeles, CaliforniaSold in CA, NY
  • Monarch Capital Group, Inc. · New York, New YorkSold in CA, NY, TX

Remarks in the notice

  • On fees: “In addition to the cash portion, Monarch Capital Group, Inc. and Antaeus Capital, Inc. have been or will be issued warrants to purchase up to 299,998 shares of common stock of the issuer with an exercise price of $0.33 per share.”

Signed by Paul Buck, Chief Financial Officer. Source: SEC Form D, newest notice filed May 9, 2011. Read the notice at the SEC.

optionsSEC
Oct 2010$2 MNo. 3Under $2 million

CNS Response, Inc.: Raise no. 3, Oct 2010

Investors in this round

4 investors had bought by the notice of Oct 18, 2010: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$66,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Hoffman · Executive Officer
  • George Carpenter · Director, Executive Officer
  • Michael Darkoch · Executive Officer
  • Paul Buck · Executive Officer
  • David Jones · Director
  • George Kallins · Director
  • Henry Harbin · Director
  • Jerome Vaccaro · Director
  • John Pappajohn · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Monarch Capital Group LLC · New York, New YorkSold in CA, IA, IL, MA, NJ, NY

Remarks in the notice

  • On fees: “Does not include cash expense allowance of up to $13,200 and warrants to purchase up to 220,000 shares.”
  • On the amounts: “Issuance and sale of Notes, for cash or in exchange for outstanding notes, of up to $3,000,000 plus accrued interest and unpaid interest on exchanged notes.”

Signed by Paul Buck, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 18, 2010. Read the notice at the SEC.

equity, debt, optionsSEC
Aug 2009$2 MNo. 2$2 to $10 million

CNS Response, Inc.: Raise no. 2, Aug 2009

Investors in this round

6 investors had bought by the notice of Sep 8, 2009: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $6 M offered; $4 M still to sell
Smallest investment taken
$54,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$771,120
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel A Hoffman · Executive Officer
  • George Carpenter · Director, Executive Officer
  • Mark Desrosiers · Executive Officer
  • David B. Jones · Director
  • Henry T. Harbin · Director
  • Jerome Vaccaro · Director
  • Len Brandt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, NySold in no state named

Remarks in the notice

  • On fees: “Commission listed is based on the Offering closing the Maximum Amount.”
  • On the amounts: “Amount listed in (a) represents the Maximum Amount to be sold in the Offering.”

Signed by George Carpenter, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 8, 2009. Read the notice at the SEC.

equity, optionsSEC
Jun 2009$1 MNo. 1Under $2 million

CNS Response, Inc.: Raise no. 1, Jun 2009

Investors in this round

1 investor had bought by the notice of Mar 18, 2010: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
$1,000,000
What was sold
options or other rights to buy securities, other: DEBT CONVERTIBLE INTO EQUITY
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel A. Hoffman · Executive Officer
  • George B. Carpenter · Executive Officer, Director
  • Paul A. Buck · Executive Officer
  • David B. Jones · Director
  • Henry T. Harbin · Director
  • Jerome B. Vaccaro · Director
  • John B. Pappajohn · Director
  • Tommy B. Thompson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Paul Buck, Chief financial officer. Source: SEC Form D, newest notice filed Mar 18, 2010. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Emmaus Life Sciences, Inc., its revenue in fiscal 2025 came from these product and service lines: Endari - US $9.05 million (73%), Endari - International $3.18 million (26%), Other $220,000 (2%).

    Annual report (SEC XBRL) · Dec 2025

  • CNS Response, Inc. had revenue between $25 million and $100 million when it filed its newest notice of a funding round (Oct 2020).

    SEC Form D (revenue range) · Oct 2020

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Oct 2020

Products and services#

No products or services of CNS Response, Inc. are on record.

Investors#

No investor of CNS Response, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 12 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by CNS Response, Inc.
NameRoleNamed in
Joseph SherwoodExecutive officerOct 2020
Willis LeeExecutive officerOct 2020
Yutaka NiiharaExecutive officerOct 2020
Daniel T. HoffmanExecutive officerMay 2011
George CarpenterExecutive officerMay 2011
Michael T. DarkochExecutive officerMay 2011
Paul T. BuckExecutive officerMay 2011
Daniel HoffmanExecutive officerOct 2010
Michael DarkochExecutive officerOct 2010
Paul BuckExecutive officerOct 2010
Daniel A. HoffmanExecutive officerMar 2010
George B. CarpenterExecutive officerMar 2010
Paul A. BuckExecutive officerMar 2010
Daniel A HoffmanExecutive officerSep 2009
Mark DesrosiersExecutive officerSep 2009
Ian Pine ZwickerDirectorOct 2020
Jane Pine WoodDirectorOct 2020
Masaharu OsatoDirectorOct 2020
Robert DickeyDirectorOct 2020
Wei Peu ZenDirectorOct 2020
Willis LeeDirectorOct 2020
Yutaka NiiharaDirectorOct 2020
David B. JonesDirectorMay 2011
George CarpenterDirectorMay 2011
George T. KallinsDirectorMay 2011
Henry T. HarbinDirectorMay 2011
Jerome B. VaccaroDirectorMay 2011
John PappajohnDirectorMay 2011
David JonesDirectorOct 2010
George KallinsDirectorOct 2010
Henry HarbinDirectorOct 2010
Jerome VaccaroDirectorOct 2010
George B. CarpenterDirectorMar 2010
John B. PappajohnDirectorMar 2010
Tommy B. ThompsonDirectorMar 2010
Len BrandtDirectorSep 2009

Went public since 2012. Its SEC number is that of a company listed on a stock exchange.